



IFW

PTO/SB/21 (09-04)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM (to be used for all correspondence after initial filing)	Application Number	10/728019-Conf. #8027
	Filing Date	December 3, 2003
	First Named Inventor	Gary L. JOHNSON
	Art Unit	1646
	Examiner Name	Not Yet Assigned
Total Number of Pages in This Submission	Attorney Docket Number	CPI-042CN2

ENCLOSURES (Check all that apply)		
<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> After Allowance Communication to TC
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Amendment/Reply	<input type="checkbox"/> Petition	<input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Terminal Disclaimer	<input checked="" type="checkbox"/> Other Enclosure(s) (please identify below):
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Request for Refund	Return Receipt Postcard
<input checked="" type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> CD, Number of CD(s) _____	PTO form SB/08
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> Landscape Table on CD	Certificate of Mailing
<input type="checkbox"/> Reply to Missing Parts/Incomplete Application	Remarks	Copies of Two (2) References
<input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53		
SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT		
Firm Name	LAHIVE & COCKFIELD, LLP	
Signature		
Printed name	Debra J. Milasincic	
Date	December 20, 2005	Reg. No. 46,931

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: December 20, 2005

Signature:

(Debra J. Milasincic)



I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: December 20, 2005 Signature: _____

(Debra J. Milasincic)

Docket No.: CPI-042CN2
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Gary L. Johnson

Application No.: 10/728019

Confirmation No.: 8027

Filed: December 3, 2003

Art Unit: 1646

For: METHOD AND PRODUCT FOR
REGULATING APOPTOSIS

Examiner: Not Yet Assigned

INFORMATION DISCLOSURE STATEMENT (IDS)

MS Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement is filed before the mailing date of a first Office Action on the merits as far as is known to the undersigned (37 CFR 1.97(b)(3)).

For the Examiner's convenience in reviewing this continuation application, Applicant/s submit/s a consolidated PTO Form SB/08, listing all references cited during the prosecution of the parent application. References A1-A5, B1-B4, C1-C55 and C57-C76 were previously cited and submitted to the Office in U.S. Application Serial No. 09/023,130, filed February 13, 1998 (Atty. Docket No. CPI-042), of which this application is a continuation and to which this application claims priority. In accordance with 37 CFR §1.98(d), these references are not enclosed herewith, but will be provided upon request. In addition, this Information Disclosure

Statement presents references C56 and C77, not previously submitted to the Office, which are enclosed herewith in accordance with 37 CFR §1.97.

Applicant has not submitted copies of each cited U.S. patent and U.S. patent application as required by 37 CFR 1.98(a)(2)(i), amended October 2004, as the U.S. Patent and Trademark Office has waived this requirement for all U.S. patent applications. Applicant submits herewith copies of foreign and non-patents in accordance with 37 CFR 1.98(a)(2).

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing of this Information Disclosure statement shall not be construed to be an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

It is submitted that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 12-0080, under Order No. CPI-042CN2. A duplicate copy of this paper is enclosed.

Dated: December 20, 2005

DJM/JRG/mch

Respectfully submitted,

By 

Debra J. Milasincic

Registration No.: 46,931

LAHIVE & COCKFIELD, LLP


28 State Street

Boston, Massachusetts 02109

(617) 227-7400

(617) 742-4214 (Fax)

Attorney/Agent For Applicant



PTO/SB/08a/b (07-05)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/728019-Conf. #8027
				Filing Date	December 3, 2003
				First Named Inventor	Gary L. JOHNSON
				Art Unit	1646
				Examiner Name	Not Yet Assigned
Sheet	1	of	4	Attorney Docket Number	CPI-042CN2

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
	A1*	US-5,405,941	04-11-1995	Johnson	
	A2*	US-5,753,446	05-19-1998	Johnson	
	A3*	US-5,854,043	12-29-1998	Johnson	
	A4*	US-5,968,781	10-19-1999	Yoon et al.	
	A5*	US-5,981,265	11-09-1999	Johnson	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
	B1*	WO-94/24159-A1	10-27-1994	National Jewish Center for Immunology		
	B2*	WO-95/28421-A1	10-26-1995	National Jewish Center for Immunology and Respiratory Medicine		
	B3*	WO-97/35014-A1	09-25-1997	Postscript, Inc.		
	B4*	WO-97/40145-A1	10-30-1997	The Regents of the University of Michigan		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. * CITE NO.: Those application(s) which are marked with an single asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T ²
	C1*	Avdi, N.J., et al., "Activation of MEKK by Formyl-methionyl-leucyl-phenylalanine in Human Neutrophils. Mapping pathways for mitogen-activated protein kinase activation," <i>J. Biol. Chem.</i> , Vol. 271:33598-33606 (1996)		
	C2*	Baeuerle, P.A., et al., "NF-(kappa)β:ten years after," <i>Cell</i> , Vol. 87:13-20 (1996)		
	C3*	Beidler, D.R., et al., "The baculovirus p 35 protein inhibits Fas- and tumor necrosis factor-induced apoptosis," <i>J. Biol. Chem.</i> , Vol. 270:16526-16528 (1996)		
	C4*	Blank, J.L., et al., "Molecular cloning of mitogen-activated protein/ERK kinase kinases (MEKK) 2 and 3. Regulation of sequential phosphorylation pathways involving mitogen-activated protein kinase and c-Jun kinase," <i>J. Biol. Chem.</i> , Vol. 271:5361-5368 (1996)		
	C5*	Blumer, K.J., et al., "Mammalian mitogen-activated protein kinase kinase kinase (MEKK) can function in a yeast mitogen-activated protein kinase pathway downstream of protein kinase C," <i>Proc. Natl. Acad. Sci. USA</i> , Vol. 91(11):4925-4929 (1994)		
	C6*	Boehringer Mannheim Biochemicals, 1994, Catalog, p. 93		
	C7*	Bork, Genome Research, 2000, 10:398-400		
	C8*	Bowie, et al., Science, 1990, 247:1306-1310		
	C9*	Burgess et al., J of Cell Bio. 111:2129-2138, 1990		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/728019-Conf. #8027
				Filing Date	December 3, 2003
				First Named Inventor	Gary L. JOHNSON
				Art Unit	1646
				Examiner Name	Not Yet Assigned
Sheet	2	of	4	Attorney Docket Number	CPI-042CN2

C10*	Cardone, M.H., et al., "The regulation of anoikis: MEKK-1 activation requires cleavage by caspases," <i>Cell</i> , Vol. 90:315-323 (1997)	
C11*	Chaleff, D.T., et al., "Molecular cloning and characterization of the <i>STE7</i> and <i>STE11</i> genes of <i>Saccharomyces cerevisiae</i> ," <i>Mol. Cell. Biol.</i> , Vol. 5(8):1878-1886 (1985)	
C12*	Darmon, A.J., et al., "An Interleukin-1 Converting Enzyme-like Protease is a Key Component of Fas-mediated Apoptosis," <i>J. Biol. Chem.</i> , Vol. 271:21699-21702 (1996)	
C13*	Ellinger-Ziegelbauer, H., et al., "Direct activation of the stress-activated protein kinase (SAPK) and extracellular signal-regulated protein kinase (ERK) pathways by an inducible mitogen-activated protein Kinase/ERK kinase kinase 3 (MEKK) derivative," <i>Journal of Biological Chemistry</i> , Vol. 272(5):2668-2674 (1997)	
C14*	Fanger, G.R., et al., "MEK kinases are regulated by EGF and selectively interact with Rac/Cdc42," <i>The EMBO Journal</i> , Vol. 16:4961-4972 (1997)	
C15*	Fanger, Gary R., et al., "MEKKs, GCKs, MLKs, PAKs, TAKs, and Tpls: upstream regulators of the c-Jun amino-terminal kinases?" <i>Current Opinion in Genetics & Development</i> , Vol. 7:67-74 (1997)	
C16*	Fernandes-Alnemri, 1996, <i>Proc Natl Acad Sci USA</i> , 93:7464-7469	
C17*	Fraser, A., et al., "A license to kill," <i>Cell</i> , Vol. 85:781-784 (1996)	
C18*	Gajewski, T.F., et al., "Apoptosis meets signal transduction: elimination of a BAD influence," <i>Cell</i> , Vol. 87:589-592 (1996)	
C19*	Gardner, A.M., et al., "Fibroblast growth factor-2 suppression of tumor necrosis factor α -mediated apoptosis requires ras and the activation of mitogen-activated protein kinase," <i>J. Biol. Chem.</i> , Vol. 271:14560-14566 (1996)	
C20*	GenBank Accession Number AAA85038: "MEKK1. (Mus musculus)" (Jan. 1, 1996)	
C21*	GenBank Accession Number AAA97500: "MEK Kinase (Mus Musculus)," (April 18, 1996)	
C22*	GenBank Accession Number AAC52596: "MAP kinase kinase kinase 1. (Rattus norvegicus)," (June 5, 1996)	
C23*	GenBank Accession Number AAC97073: "MEK kinase 1. (Homo sapiens)," (Dec. 17, 1998)	
C24*	GenBank Accession Number AAD25049: "Map kinase kinase kinase 1 (Mus musculus)," (April 14, 1999)	
C25*	GenBank Accession Number AB014614, "Mus musculus mRNA for MEKK1 N-terminal," (Oct. 29, 1999)	
C26*	GenBank Accession Number AF042838: "Homo sapiens MEK kinase 1 (MEKK1) mRNA," (Dec. 18, 1998)	
C27*	GenBank Accession Number AF117340: "Mus musculus MAP kinase kinase kinase 1 (MEKK1) mRNA," (April 14, 1999)	
C28*	GenBank Accession Number BAA85878: "MEKK1 N-terminal (Mus musculus)," (Oct. 29, 1999)	
C29*	GenBank Accession Number L13103: "Mus musculus MEK kinase mRNA," (April 18, 1996)	
C30*	GenBank Accession Number NP_006600: "Mitogen-activated protein kinase kinase kinase 2. (Homo sapiens)," (Sept. 16, 1999)	
C31*	GenBank Accession Number U23470: Mus musculus Map kinase kinase (MEKK1) mRNA," (Jan. 4, 1996)	
C32*	GenBank Accession Number U48596: "Rattus norvegicus MAP kinase kinase kinase 1(MEKK1) mRNA," (June 5, 1996)	
C33*	Gerwins, Pär, et al., "Cloning of a Novel Mitogen-activated Protein Kinase Kinase Kinase, MEKK4, That Selectively Regulates the c-Jun Amino Terminal Kinase Pathway," <i>The Journal of Biological Chemistry</i> , Vol. 272(13):8288-8295 (1997)	
C34*	Hirano, M., et al., "MEK kinase is involved in tumor necrosis factor α -induced NF- κ B activation and degradation by I κ B- α ," <i>J. Biol. Chem.</i> , Vol. 271:13234-13238 (1996)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/728019-Conf. #8027
				Filing Date	December 3, 2003
				First Named Inventor	Gary L. JOHNSON
				Art Unit	1646
				Examiner Name	Not Yet Assigned
Sheet	3	of	4	Attorney Docket Number	CPI-042CN2

C35*	Howard, A.D., et al., "IL-1-converting enzyme requires aspartic acid residues for processing of the IL-1 β precursor at two distinct sites and does not cleave 31-kDa IL-1 α ," <i>J. Immunol.</i> , Vol. 147:2964-2969 (1991)	
C36*	Hu, M.C., et al., "Human HPK1, a novel human hematopoietic progenitor kinase that activated the JNK/SAPK kinase cascade," <i>Genes Dev.</i> , Vol. 10:2251-2264 (1996)	
C37*	Johnson, N.L., et al., "Signal transduction pathways regulated by mitogen-activated/extracellular response kinase kinase kinase induce cell death," <i>Journal of Biological Chemistry</i> , Vol. 271(6):3229-3237 (1996)	
C38*	Juo, P., et al., "Fas activation of the p38 mitogen-activated protein kinase signalling pathway requires ICE/CED-3 family proteases," <i>Mol. Cell. Biol.</i> , Vol. 17:24-35 (1997)	
C39*	Karin, M., et al., "JNK or IKK, AP-1 or NF κ B, which are targets for MEK kinase 1 action?" <i>Proc. Natl. Sci., USA</i> , Vol. 95:9067-9069 (1998)	
C40*	Khokhlatchev, A., et al., "Reconstitution of mitogen-activated protein kinase phosphorylation cascades in bacteria. Efficient synthesis of active protein kinases," <i>Journal of Biological Chemistry</i> , Vol. 272(17):11057-11062 (1997)	
C41*	Kyriakis, J.M., et al., "Raf-1 activates MAP kinase-kinase," <i>Nature</i> , Vol. 358(6385):417-421 (1992)	
C42*	Lange-Carter, C.A., et al., Science 260: 315-319 and MPSRCH search report, 2003, us-09-858-754-3-copy-875-1493.rsp, pages 1-2	
C43*	Lange-Carter, C.A., et al., "A divergence in the MAP kinase regulatory network defined by MEK kinase and Raf," <i>Science</i> , Vol. 260:315-319 (1993)	
C44*	Lange-Carter, C.A., et al., "Ras-dependent growth factor regulation of MEK kinase in PC12 cells," <i>Science</i> , Vol. 265:1458-1461 (1994)	
C45*	Lassignal Johnson, N., et al., "Signal transduction pathways regulated by mitogen-activated/extracellular response kinase kinase kinase induce cell death," <i>J. Biol. Chem.</i> , Vol. 271:3229-3237 (1996)	
C46*	Lazar, Eliane, et al., "Transforming Growth Factor α : Mutation of Aspartic Acid 47 and Leucine 48 Results in Different Biological Activities," <i>Molecular and Cellular Biology</i> , Vol. 8(3):1247-1252 (1988)	
C47*	Liu, Z.-G., et al., "Three distinct signalling response by murine fibroblasts to genotoxic stress," <i>Nature</i> , Vol. 384:273-276 (1996)	
C48*	Liu, Z.-G., et al., "Dissection of TNF receptor 1 effector functions: JNK activation is not linked to apoptosis while NF- κ B activation prevents cell death," <i>Cell</i> , Vol. 87:565-576 (1996)	
C49*	Los, M., et al., "Requirement of an ICE/CED-3 protease for Fas/APO-1-mediated apoptosis," <i>Nature</i> , Vol. 375:81-83 (1995)	
C50*	Minden, Audrey, et al., "Differential Activation of ERK and JNK Mitogen-Activated protein Kinases by Raf-1 and MEKK," <i>Science</i> , Vol. 266:1719-1723 (1994)	
C51*	MPSRCH Search Report, 2003, us-09-858-754-3-copy-875-1493.rag, pages 1-2	
C52*	MPSRCH search report, 2003, us-09-858-754-3-copy-875-1493.rag, pages 3-4	
C53*	Nicholson, D.W., et al., "Identification and inhibition of the ICE/CED-3 protease necessary for mammalian apoptosis," <i>Nature</i> , Vol. 376:37-43 (1995)	
C54*	PIR Accession No. A46212; MEK Kinase - mouse	
C55*	Russell, M., et al., "Direct interaction between Ras and the kinase domain of mitogen-activated protein kinase kinase kinase (MEKK1)," <i>Journal of Biological Chemistry</i> , Vol. 270:11757-11760 (1995)	
C56	Schaefer, Brian C., et al., "Live Cell Fluorescence Imaging of T Cell MEKK2: Redistribution and Activation in Response to Antigen Stimulation of the T Cell Receptor," <i>Immunity</i> , Vol. 11:411-421 (1999)	
C57*	Schlesinger, T.K., et al., "The Tao of MEKK," <i>Front. Biosci.</i> , Vol. 3:D1181-1186 (1998)	
C58*	Seger, R., et al., "The MAPK signaling cascade," <i>FASEB J.</i> , Vol. 9:726-735 (1995)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/728019-Conf. #8027
				Filing Date	December 3, 2003
				First Named Inventor	Gary L. JOHNSON
				Art Unit	1646
				Examiner Name	Not Yet Assigned
Sheet	4	of	4	Attorney Docket Number	CPI-042CN2

C59*	Su, B., et al., "JNK is involved in signal integration during costimulation of T lymphocytes," <i>Cell</i> , Vol. 77:727-736 (1994)	
C60*	Sumimoto, S.-I., et al., "Involvement of LFA-1/intracellular adhesion molecule-1-dependent cell adhesion in CD40-mediated inhibition of human B lymphoma cell death induced by surface IgM crosslinking," <i>J. Immunol.</i> , Vol. 153:2488-2496 (1994)	
C61*	SWISS-PROT Accession No. P53349; MAPK/ERK KINASE 1 (MEK KINASE 1) (MEKK 1)	
C62*	SWISS-PROT Accession No. Q62925; MAPK/ERK KINASE 1 (MEK KINASE 1) (MEKK 1)	
C63*	Tsubata, T., et al., "B-cell apoptosis induced by antigen receptor crosslinking is blocked by a T-cell signal through CD40," <i>Nature</i> , Vol. 364:645-648 (1993)	
C64*	Winston, B.W., et al., "Tumor necrosis factor alpha rapidly activates the mitogen-activated protein kinase (MAPK) cascade in a MAPK kinase kinase-dependent, c-Raf-1-independent fashion in mouse macrophages," <i>Proc. Natl. Acad. Sci. USA</i> , Vol. 92:1614-1618 (1995)	
C65*	Xia, Y., et al., "JNKK1 organizes a MAP kinase module through specific and sequential interactions with upstream and downstream components mediated by its amino-terminal extension," <i>Genes Dev.</i> , Vol. 12(21):3369-3381 (1998)	
C66*	Xu, S., et al., "MEKK1 binds directly to the c-Jun N-terminal kinases/stress-activated protein kinases," <i>Journal of Biological Chemistry</i> , Vol. 272(15):32056-32060 (1997)	
C67*	Xu, S., et al., "MEKK1 phosphorylates MEK1 and MEK2 but does not cause activation of mitogen-activated protein kinase," <i>Proc. Natl. Acad. Sci. USA</i> , Vol. 92(15):6808-6812 (1995)	
C68*	Yan, M., et al., "Activation of stress-activated protein kinase by MEKK1 phosphorylation of its activator SEK1," <i>Nature</i> , Vol. 372(6508):798-800 (1994)	
C69*	Yujiri, T., et al., "Role of MEKK1 in cell survival and activation of JNK and ERK pathways defined by targeted gene disruption," <i>Science</i> , Vol. 282(5395):1911-1914 (1998)	
C70*	Verhegi, M., et al., "Requirement for ceramide-initiated SAPK/JNK signalling in stress-induced apoptosis," <i>Nature</i> , Vol. 380:75-79 (1996)	
C71*	Wang, Y., et al., "byr2, a <i>Schizosaccharomyces pombe</i> gene encoding a protein kinase capable of partial suppression of the <i>ras1</i> mutant phenotype," <i>Mol. Cell. Biol.</i> , Vol. 11(7):3554-3563 (1991)	
C72*	Widmann, C., et al., "Caspase-dependent cleavage of signaling proteins during apoptosis. A turn-off mechanism for anti-apoptotic signals," <i>J. Biol. Chem.</i> , Vol. 273:7141-7147 (1998)	
C73*	Widmann, C., et al., "MEK kinase 1, a substrate for DEVD-directed caspases, is involved in genotoxin-induced apoptosis," <i>Mol. Cell. Biol.</i> , Vol. 18:2416-2429 (1998)	
C74*	Widmann, C., et al., "Potentiation of apoptosis by low dose stress stimuli in cells expressing activated MEK kinase 1," <i>Oncogene</i> , Vol. 15:2439-2447 (1997)	
C75*	Xia, Z., et al., "Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis," <i>Science</i> , Vol. 270:1326-1331 (1995)	
C76*	Xu, S., et al., "Cloning of rat MEK kinase 1 cDNA reveals an endogenous membrane-associated 195-kDa protein with a large regulatory domain," <i>Proc. Natl. Acad. Sci. USA</i> , Vol. 93:5291-5295 (1996)	
C77	International Search Report Application No. PCT/US99/02974, dated July 22, 1999	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

*Applicant's unique citation designation number (optional). *Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

Application No. (if known): 10/728019


Attorney Docket No.: CPI-042CN2

Certificate of Mailing under 37 CFR 1.8

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to:

MS Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

on December 20, 2005
Date


Signature

Debra J. Milasincic

Typed or printed name of person signing Certificate

46,931
Registration Number, if applicable

(617) 227-7400
Telephone Number

Note: Each paper must have its own certificate of mailing, or this certificate must identify each submitted paper.

Return Receipt Postcard
Transmittal (1 page)
Information Disclosure Statement (2 pages, in duplicate)
PTO form SB/08 (86 references) (4 pages)
Copies of Two (2) References